Agenus Inc. (NASDAQ:AGEN)

Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company’s product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.

Agenus Inc. (NASDAQ:AGEN)’s Financial Overview

Agenus Inc. (NASDAQ:AGEN) declined -5.29% yesterday to close its trading session at $4.12. The company has 1 year Price Target of $7.95. Agenus Inc. has 52-Week high of $7.49 and 52-Week Low of $2.61. The stock touched its 52-Week High on Oct 5, 2016 and 52-Week Low on Feb 11, 2016. The stock traded with the volume of 2.44 Million shares yesterday. The firm shows the market capitalization of $358.48 Million.

Agenus Inc. (NASDAQ:AGEN) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $-0.47/share against the analyst consensus estimate of $-0.3/share. The difference between the actual and expected EPS is $-0.17 a share with a surprise factor of -56.7%.

The firm is trading with SMA20 of -12.8 Percent, SMA50 of -27.69 Percent and SMA200 of -14.15 percent. Agenus Inc. has P/S value of 14.57 while its P/B value stands at 0. Similarly, the company has Return on Assets of -55.9 percent, Return on Equity of -420.4 percent and Return on Investment of -40.7 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.

Many brokerage firms are involved in issuing their ratings on Agenus Inc. (NASDAQ:AGEN). On 28-Oct-16 H.C. Wainwright Downgrade Agenus Inc. Stock  to Neutral. Another firm also rated the stock on 11-Mar-16 where Maxim Group Upgrade the stock to Buy.

The Stock currently has Analyst’ mean Recommendation of 1.8 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 4 analysts offering 12-month price forecasts for Agenus Inc have a median target of 7.00, with a high estimate of 15.00 and a low estimate of 5.00. The median estimate represents a +69.90% increase from the last price of 4.12.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

DexCom, Inc. (NASDAQ:DXCM)

Dexcom Inc. is developing continuous glucose monitoring systems for people with diabetes.

DexCom, Inc. (NASDAQ:DXCM)’s Financial Outlook

The 18 analysts offering 12-month price forecasts for DexCom Inc have a median target of 88.50, with a high estimate of 110.00 and a low estimate of 56.75. The median estimate represents a +35.55% increase from the last price of 65.29.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, DexCom, Inc. has a Consensus Recommendation of 1.73. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -4.08% and closed its last trading session at $65.29. The company has the market capitalization of $5.52 Billion. The stock has 52-week high of $96.38 and 52-Week low of $47.92. The firm touched its 52-Week high on Sep 8, 2016 and 52-Week low on Feb 8, 2016. The company has volume of 5.73 Million shares. The company has a total of 84.52 Million shares outstanding.

DexCom, Inc. (NASDAQ:DXCM) in the last quarter reported its actual EPS of $-0.22/share where the analyst estimated EPS was $-0.13/share. The difference between the actual and Estimated EPS is $-0.09. This shows a surprise factor of -69.2 percent.

The company has YTD performance of -20.28 percent. Beta for DexCom, Inc. stands at 0.55 while its ATR (average true range) is 3.63. The company has Weekly Volatility of 5.31%% and Monthly Volatility of 5.10%%.

DexCom, Inc. has distance from 20-day Simple Moving Average (SMA20) of -4.01%, Distance from 50-Day Simple Moving Average of -16.17 percent and Distance from 200-Day Simple Moving Average of -13.34%.

The Company currently has ROA (Return on Assets) of -17.6 percent, Return on Equity (ROE) of -23.6 Percent and Return on Investment (ROI) of -25.6% with Gross margin of 66.2 percent and Operating & Profit margin of -10.5% and -10.6% respectively.